You first have to discover the patients in medical databases whove recurrent cancer.

They did not. For example, a newly diagnosed secondary cancer might not tag a recurrence but may instead be considered a new cancer entirely; a second, later round of chemotherapy could be necessary for continuing control of the de novo cancer, and not to treat recurrence. ‘Fundamentally, these algorithms don't work for all malignancy sites in lots of datasets commonly utilized for cancer research,’ says Ritzwoller. For instance, to discover recurrent prostate cancer, no combination of billing codes found in this huge data set pointed with sensitivity and specificity to individuals whom notes in the data showed acquired recurrent disease.AEterna Zentaris terminates its agreement on cetrorelix with sanofi-aventis U.S. AEterna Zentaris Inc. , a global biopharmaceutical company focused on oncology and endocrine therapy, today announced the termination of its contract with sanofi-aventis U.S. dated March 5, 2009 for the advancement, commercialization and licensing of cetrorelix in benign prostatic hyperplasia for the U.S. Market, following the Company’s announcement last week of the results because of its European Phase 3 study for cetrorelix in BPH.